Liver Cirrhosis Completed Phase 3 Trials for Tolvaptan (DB06212)

Also known as: Cirrhosis, Liver / Cirrhosis / Cirrhosis (of liver) NOS / Cirrhosis of liver / Cirrhosis liver / Hepatic cirrhosis NOS / Hepatic cirrhosis

IndicationStatusPhase
DBCOND0028911 (Liver Cirrhosis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01048788A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mgTreatment
NCT01050530A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic EdemaTreatment
NCT01114828A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic EdemaTreatment
NCT01556646Effect of Tolvaptan on Cognitive Function in CirrhosisTreatment
NCT01850940Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia